IP Verse

Use Of Carbamate Compounds For Prevention, Alleviation Or Treatment Of Bipolar Disorder

Patent No. EP3556366 (titled "Use Of Carbamate Compounds For Prevention, Alleviation Or Treatment Of Bipolar Disorder") was filed by SK Biopharmaceuticals on Dec 14, 2017. The application was issued on Oct 23, 2019.

Patent Summary

Patent Family

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Nov 4, 2025
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Sep 25, 2025
Decision to grant a European patent
Sep 22, 2025
Request for a change to the title of the invention
Jul 22, 2025
(Electronic) Receipt
Jul 22, 2025
Filing of the translations of the claims
Jul 22, 2025
French translation of claims
Jul 22, 2025
German translation of the claims
Jul 22, 2025
Letter accompanying subsequently filed items
Mar 25, 2025
Annex to the communication about intention to grant a European patent
Mar 25, 2025
Bibliographic data of the European patent application
Mar 25, 2025
Communication about intention to grant a European patent
Mar 25, 2025
Intention to grant (signatures)
Mar 25, 2025
Text intended for grant (clean copy)
Mar 25, 2025
Text intended for grant (version for approval)
Mar 20, 2025
Bibliographic data of the European patent application
Nov 10, 2023
(Electronic) Receipt
Nov 10, 2023
Amended claims with annotations
Nov 10, 2023
Amended description with annotations
Nov 10, 2023
Claims
Nov 10, 2023
Description
Nov 10, 2023
Letter accompanying subsequently filed items
Nov 10, 2023
Reply to communication from the Examining Division
Jun 30, 2023
Annex to the communication
Jun 30, 2023
Communication from the Examining Division
Jun 27, 2023
Examination started
Dec 15, 2020
(Electronic) Receipt
Dec 15, 2020
Amended claims filed after receipt of (European) search report
Dec 15, 2020
Amended claims with annotations
Dec 15, 2020
Amendments received before examination
Dec 15, 2020
Letter accompanying subsequently filed items
Dec 15, 2020
Non-patent literature cited during the examination procedure
Dec 15, 2020
Non-patent literature cited during the examination procedure
Jun 5, 2020
Invitation to declare maintenance of the application and to correct deficiencies in the Written Opinion/amend application
May 18, 2020
Communication regarding the transmission of the European search report
May 18, 2020
European search opinion
May 18, 2020
Information on Search Strategy
May 18, 2020
Supplementary European search report
May 6, 2020
Search started
Feb 7, 2020
Amended claims filed after receipt of (European) search report
Feb 7, 2020
Amended claims with annotations
Feb 7, 2020
Amendments received before examination
Sep 25, 2019
Notification of forthcoming publication
Jul 31, 2019
Communication regarding possible amendment of the application/payment of claims fee
Jul 29, 2019
Communication to designated inventor
Jul 29, 2019
Communication to designated inventor
Jul 11, 2019
(Electronic) Receipt
Jul 11, 2019
Abstract
Jul 11, 2019
Claims
Jul 11, 2019
Description
Jul 11, 2019
Drawings
Jul 11, 2019
Request for entry into the European phase
Jul 2, 2019
Copy of the international preliminary report on patentability
Jul 2, 2019
Translation of the international preliminary report on patentability
Apr 26, 2019
Information on entry into European phase
Jul 16, 2018
Priority document (electronically transmitted)
Jun 21, 2018
Copy of the international search report
Jun 21, 2018
Copy of the translated international search report
Jun 21, 2018
International publication pamphlet

EP3556366

SK BIOPHARMACEUTICALS

Application Number: EP17881161A
Filing Date: Dec 14, 2017
Status: Intended To Grant; Mar 24, 2025
Publication Date: Oct 23, 2019
External Links: Slate, Register , Google Patents